Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25181675 | 1.00 | NR1H2 (0.43) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL19719160 | 1.00 | NR1H2 (0.43) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL18418133 | 1.00 | NR1H2 (0.43) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL25181672 | 1.00 | NR1H2 (0.43) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL25699186 | 1.00 | NR1H2 (0.43) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL25185151 | 0.90 | HPGD (0.41) | USP2SMN1; SMN2HPGDGPR119PDE4B | |
| SCHEMBL14606052 | 0.86 | NR1H2 (0.46) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL5591325 | 0.86 | NR1H2 (0.46) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL23214845 | 0.85 | NR1H2 (0.51) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL23215563 | 0.85 | NR1H2 (0.48) | NR1H2DDB1CRBNUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | NR1H2 1461/4885DDB1 1823/4885CRBN 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.